Topic: Clinical Trial Results
The chronicles of Aslan keep reading as a tragedy as the Singapore-based cancer biotech is hit with another failure for its key pipeline hope.
The lackluster results led Syros to switch its attention to an oral CDK7 inhibitor, SY-5609, that is due to enter the clinic early next year.
Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.
The positive result tees Reata up to file for FDA approval of the activator of Nrf2 and expand development to other neurodegenerative diseases.
Expectations for NASH are still sky-high—some see billions for any drug that gets it right at peak—but the reality of clinical trials has been murky.
Arbutus Biopharma is dumping one of its Roivant-backed programs after two healthy people in a phase 1 study developed acute hepatitis.
Amgen posted what appeared to be an innocuous update about it drug Kyprolis and other pipeline assets, but a deeper read turned up a nasty surprise.
Patient groups in the U.K. are fed up with a perceived pushback from the organization set up to try to promote clinical trial transparency.
AstraZeneca’s AZD1775 extended median survival in pancreatic cancer when combined with chemo and radiation in a phase 1 trial.
Turning Point’s update on repotrectinib in NSCLC showed more than four-fifths of patients responded to the drug, but its stock fell 10%.